Fri, Apr 03, 2020
Hyderabad-based Aurobindo Pharma's decision to break its deal with Sandoz will likely impact the company and its stocks according to analysts who track the sector. The biggest reason why this decision has been taken is due to the company not getting approval from US Federal Trade Commission (FTC)
More >
Fri, Sep 07, 2018
With the blockbaster performance of today Aurobindo Pharma has now given a performance of 56.78% in a year.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
